[144] ANI Pharmaceuticals, Inc. SEC Filing
Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.
- None.
- None.
Insights
TL;DR: Insider sale disclosed; transaction size is small relative to total shares outstanding and appears routine.
The filing notifies the market of a planned sale of 7,292 common shares through Morgan Stanley Smith Barney with an indicated value of $692,270.40 and references recent restricted stock grants and a recent sale of 5,421 shares generating $486,406.81. With 21,688,772 shares outstanding, the planned sale represents roughly 0.03% of outstanding shares, suggesting limited immediate dilution or market impact. The disclosure is consistent with Rule 144 mechanics for restricted securities and includes the standard attestation about undisclosed material information.
TL;DR: Document fulfills disclosure obligations under Rule 144; provides dates and amounts for grants and recent sales.
The filer documents acquisition dates for restricted stock awards and lists a broker and planned sale date, meeting procedural requirements for public notice of proposed insider sales. The filing contains the prescribed representation regarding material nonpublic information and highlights a recent sale within the last three months. There are no statements here about changes in management, related-party issues, or other governance events; thus the filing appears to be a routine transparency disclosure rather than a governance red flag.